ClinVar Miner

Submissions for variant NM_000642.3(AGL):c.2670del (p.Pro891fs)

dbSNP: rs764591009
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000658137 SCV000779908 pathogenic not provided 2018-05-22 criteria provided, single submitter clinical testing The c.2670delT variant in the AGL gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. The c.2670delT variant causes a frameshift starting with codon Proline 891, changes this amino acid to a Leucine residue, and creates a premature Stop codon at position 9 of the new reading frame, denoted p.Pro891LeufsX9. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.2670delT variant is not observed at any significant frequency in large population cohorts (Lek et al., 2016). We interpret c.2670delT as a pathogenic variant.
Invitae RCV001062864 SCV001227687 pathogenic Glycogen storage disease type III 2022-02-07 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Pro891Leufs*9) in the AGL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AGL are known to be pathogenic (PMID: 19299494). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 546284). This variant has not been reported in the literature in individuals affected with AGL-related conditions. This variant is present in population databases (rs764591009, gnomAD 0.007%).
Genome-Nilou Lab RCV001062864 SCV002055488 pathogenic Glycogen storage disease type III 2021-07-15 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV001062864 SCV002809866 likely pathogenic Glycogen storage disease type III 2021-11-10 criteria provided, single submitter clinical testing
Baylor Genetics RCV001062864 SCV004215235 pathogenic Glycogen storage disease type III 2023-06-19 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.